Sildenafil reduces Raynaud's frequency in patients with systemic sclerosis, study finds
Tuesday, March 8, 2011 - 10:05
in Health & Medicine
Researchers in Europe report that treatment with modified-release sildenafil significantly reduced the frequency of attacks of Raynaud’s phenomenon in patients with limited cutaneous systemic sclerosis (lcSSc), also known as scleroderma. The double-blind, placebo-controlled trial found that sildenafil was well tolerated with only some subjects experiencing minor or moderate side effects.